Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Dihydromyricetin for Alcohol-Associated Liver Disease
NCT05623501Phase 1Not yet recruiting
- Sponsor
- University of Southern California
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dihydromyricetin in alcohol-associated liver disease (ALD) (4 cohorts), sponsored by University of Southern California. Primary endpoints: Pharmacokinetic of DHM at 24 hours and Adverse Events at 24 hours. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
dihydromyricetin
03
Conditions
alcohol-associated liver disease (ALD)
Beyond the preview
Go deeper on NCT05623501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623501.